Morphic to Participate in Jefferies IBD Therapeutics Summit

WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021 at 3:15 p.m. ET.

A live webcast of the Jefferies fireside chat will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

ContactsMorphic TherapeuticChris Erdman[email protected]617.686.1718

Media ContactTom Donovan, Ten Bridge Communications [email protected] 857.559.3397

You May Also Be Interested In

• Cabot Corporation Prices $350 Million 4.950% Senior Notes Due 2029
• Bird Reports 2026 Second Quarter Results; 23% Revenue Growth and $12 Billion Combined Backlog
• Gatsby's Clothier Expands With Made-to-Measure Menswear and Luxury Brands